Shingrix (Herpes Zoster vaccine Recombinant, adjuvanted)

Product menu

How can you help to protect more of your eligible patients from shingles?

Is your practice seizing the opportunity to...

  • Help to protect even more of your patients from shingles?1
  • Reduce the burden of shingles on your practice and patients through prolonged reductions in Herpes Zoster and Post-Herpetic Neuralgia GP appointments?2
  • Boost your practice Quality and Outcomes Framework (QOF) indicator and receive an item of service fee per dose of shingles vaccination administered in line with national guidance?3,4

  • 1. Identify and invite patients eligible for a shingles vaccination, using your call and recall systems

    Eligibility for the Shingles National Immunisation Programme:

    NA

    For more information and support on severely immunocompromised individuals, visit our dedicated pages:

    Explore severely IC eligibility

    For more information on the eligibility criteria for the Shingles National Immunisation Programme refer to the Greenbook chapter 28a1.

    Patients become eligible for shingles vaccination each week. Run searches for eligible patients frequently e.g. once a fortnight or once a month, to facilitate a methodical and manageable approach to vaccinating eligible patients in a timely manner.

    Resource:

    Do you use EMIS Web, EMIS V2 or SystmOne and need support running searches for patients eligible for shingles vaccination?

    For practice's that do not use Arden's, GSK (in partnership with with Interface Clinical Systems) has developed pre-populated system searches compiling SNOMED codes indicating eligibility for shingles vaccination.†

    Download system searches for patient identification from illuminate

    Visit Illuminate, GSK’s dedicated community-driven platform designed by Immunisation Leads, for support with identifying your practice’s eligible patients†:

    Download System Searches for Patient Identification
    This link will take you to illuminate, a GSK owned website that contains promotional information

    †The system searches have been developed by GSK in partnership with Interface Clinical Services. They do not make clinical decisions and are not intended to replace individual clinical judgement of the HCP using the search outputs. Clinical review is required of the lists created.

    As you call patients in for dedicated vaccination clinics across winter, how can you also plan for shingles clinics?

    During winter, some of your patients attending clinics may be eligible for non-seasonal shingles vaccination. Seize this opportunity to:

    1. Proactively call and recall all eligible patients and book them in for their 1st and 2nd dose
    2. Discuss the value of vaccination against shingles and the importance of completing both doses
    3. Answer any questions your patients may have, and share helpful patient resources

    Resource

    Use the eligibility checker on Illuminate, to find out in minutes if your patient is eligible for shingles vaccination, inputting only your patients date of birth and health status:

    Visit the eligibility checker
    This link will take you to illuminate, a GSK owned website that contains promotional information

  • How many of your eligible patients have been vaccinated against shingles so far?

    More of your patients become eligible for the shingles vaccination each week, and remain unprotected until they receive their 2-dose vacciantion.

    Why run dedicated clinics?

    Running dedicated clinics all year round can be an effective way to ensure eligible patients are consistently being booked in for their shingles vaccination. These patients may otherwise be missed if relying solely on opportunistic vaccinations.

    Your proactive planning can help to protect your eligible patients from shingles.

    Did you know?

    In Sept 2013, the Shingles National Immunisation Programme was introduced into the routine schedule for adults aged 70 years with a phased catch-up programme for 71-79 years.

    In the first 5 years (which reflects use of a live shingles vaccine in the programme), for shingles and PHN there were

    • 40,500 fewer GP consultations
    • 1,840 fewer hospitalisations.2

    Through effective implementation of the Shingles National Immunisation Programme, you may reduce the burden of herpes zoster and post-herpetic neuralgia on your practice.

    Guidance to run your dedicated clinics

    Seize the opportunity to help protect eligible patients in a way that is manageable for your practice, by proactively planning and implementing dedicated shingles clinics.

    During the winter season when multiple seasonal vaccinations are offered, there is the possibility to dedicate any unused clinic appointments scheduled for seasonal vaccinations to administer shingles vaccination to eligible patients.

    Visit illuminate, GSK’s dedicated community-driven platform designed by Immunisation Leads, to learn from experts who are effectively implementing the Shingles National Immunisation Programme.

    Did you know?

    In addition to item of service payments, the Shingles National Immunisation Programme earns Quality and Outcomes Framework (QOF) points3,4

    Resource

    Visit Illuminate for a step-by-step comprehensive checklist on how to deliver the Shingles National Immunisation Programme

    Download Checklist
    This link will take you to illuminate, a GSK owned website that contains promotional information

  • Vaccines for the Shingles National Immunisation Programme are centrally procured and available to order via ImmForm. Ensure your GP surgery has sufficient stock for planned clinics along with any opportunistic vaccinations.

  • SHINGRIX is given as a 2 dose schedule1,5,6. The national guidance for administration of the 2nd dose as part of the National Immunisation Programme differs from the SPC.

    The 2nd dose of SHINGRIX is required for maximum protection against shingles, and is not a booster. Ensure you are proactively booking your patients in for their second dose, and let them know their requirement to receive it.

  • Ensure members of the public are aware of:

    • The Shingles National Immunisation Programme
    • Their eligibility for vaccination
    • The potential risk of shingles and the potential to impact their quality of life

    Raising awareness with patients is an essential step when implementing the programme, and GSK have a range of programme awareness materials available to order.

    When discussing the shingles vaccination with your patients, it’s key that patients understand the disease burden of shingles and the value of shingles vaccination, and that you are taking the time to answer any questions they may have.

    Order the below to ensure patients are aware of both SHINGRIX doses and are remembering to return, so that no patient misses out on their 2nd dose.

    Materials to educate your patients:

    NA

    Patient leaflet

    to give your patients information on shingles and the vaccination

    Order now

    Materials to support your patients with taking ownership for their course completion:

    NA

    Vaccination record card

    to help patients remember to receive their 2nd dose

    Order now

References:

  1. UKHSA Green Book: Ch28a Shingles (March 2024)
  2. Andrews N, Stowe J, Kuyumdzhieva G, et al. BMJ Open 2020; 10e037458: 1-15.
  3. UK Health Security Agency: Introduction of Shingrix vaccine for the whole programme and expansion of eligible cohorts letter. Published 4th July 2023.
  4. NHS England. Quality and Outcomes Framework Guidance for 2024/25. Published April 2024. Available at: https://www.england.nhs.uk/wp-content/uploads/2024/03/PRN01104-Quality-and-outcomes-framework-guidance-for-2024-25.pdf
  5. SHINGRIX. Summary of Product Characteristics (GB)
  6. SHINGRIX. Summary of Product Characteristics (NI)

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com

SHINGRIX is owned by or licensed to the GSK group of companies.
© 2025 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

March 2025 | PM-GB-SGX-WCNT-230025 (V4.0)